Dyne Therapeutics (DYN) Cash & Equivalents (2019 - 2026)

Dyne Therapeutics' Cash & Equivalents history runs 8 years deep, the most recent figure standing at $753.1 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 59.47% year-over-year to $753.1 million; the TTM figure through Mar 2026 stood at $753.1 million (up 59.47% YoY), while the FY2025 annual figure was $893.4 million, up 105.16% from the prior year.
• Cash & Equivalents was $753.1 million for Q1 2026 at Dyne Therapeutics, down from $893.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $893.4 million in Q4 2025 to a low of $121.6 million in Q4 2023.
• Historically, Cash & Equivalents has averaged $361.2 million across 5 years, with a median of $272.0 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents sank 59.12% in 2022, then surged 308.48% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $172.1 million in 2022, then declined by 29.35% to $121.6 million in 2023, then jumped by 258.02% to $435.4 million in 2024, then jumped by 105.16% to $893.4 million in 2025, then decreased by 15.7% to $753.1 million in 2026.
• The last three Cash & Equivalents figures came in at $753.1 million (Q1 2026), $893.4 million (Q4 2025), and $573.6 million (Q3 2025), per Business Quant data.